Reduction of PMWS-associated clinical signs and co-infections by vaccination against PCV2.
about
Porcine circovirus type 2 in China: an update on and insights to its prevalence and controlRecombinant Flagellin-Porcine Circovirus Type 2 Cap Fusion Protein Promotes Protective Immune Responses in MiceImmunity Elicited by an Experimental Vaccine Based on Recombinant Flagellin-Porcine Circovirus Type 2 Cap Fusion Protein in PigletsReliability of operational data from pig herds and performance ratings by veterinarians and pig farmers collected during telephone interviews for the evaluation of a PCV2 piglet vaccination.Induction of a robust immunity response against novel duck reovirus in ducklings using a subunit vaccine of sigma C proteinThe M/GP(5) glycoprotein complex of porcine reproductive and respiratory syndrome virus binds the sialoadhesin receptor in a sialic acid-dependent manner.Porcine reproductive and respiratory syndrome virus infection at the time of porcine circovirus type 2 vaccination has no impact on vaccine efficacy.A live-attenuated chimeric porcine circovirus type 2 (PCV2) vaccine is transmitted to contact pigs but is not upregulated by concurrent infection with porcine parvovirus (PPV) and porcine reproductive and respiratory syndrome virus (PRRSV) and is efPCV2 vaccination induces IFN-γ/TNF-α co-producing T cells with a potential role in protection.Assessing PCV2 antibodies in field pigs vaccinated with different porcine circovirus 2 vaccines using two commercial ELISA systemsVaccination of dams increases antibody titer and improves growth parameters in finisher pigs subclinically infected with porcine circovirus type 2.Studies on porcine circovirus type 2 vaccination of 5-day-old piglets.Detection of porcine circovirus type 1 in commercial porcine vaccines by loop-mediated isothermal amplificationImpact of maternally derived immunity on piglets' immune response and protection against porcine circovirus type 2 (PCV2) after vaccination against PCV2 at different ageComparison of Porcine circovirus type 2 (PCV2) infection in light and heavy pigs of market age on farms with routine PCV2 vaccination.Recognition of the different structural forms of the capsid protein determines the outcome following infection with porcine circovirus type 2.Economic efficiency analysis of different strategies to control post-weaning multi-systemic wasting syndrome and porcine circovirus type 2 subclinical infection in 3-weekly batch system farms.Effect of porcine circovirus type 2 (PCV2) vaccination of the dam on PCV2 replication in uteroA live-attenuated and an inactivated chimeric porcine circovirus (PCV)1-2 vaccine are both effective at inducing a humoral immune response and reducing PCV2 viremia and intrauterine infection in female swine of breeding age.Effect of porcine circovirus type 2 (PCV2) vaccination on PCV2-viremic piglets after experimental PCV2 challenge.Comparison of four commercial one-dose porcine circovirus type 2 (PCV2) vaccines administered to pigs challenged with PCV2 and porcine reproductive and respiratory syndrome virus at 17 weeks postvaccination to control porcine respiratory disease comInsect cell technology is a versatile and robust vaccine manufacturing platform.Best practice and future challenges for vaccination against porcine circovirus type 2.Immune Control of PRRS: Lessons to be Learned and Possible Ways Forward.Influence of porcine circovirus type 2 vaccination on the level of antimicrobial consumption on 65 Austrian pig farms.Induction of humoral immune response in piglets after perinatal or post-weaning immunization against porcine circovirus type-2 or keyhole limpet hemocyanin.Vaccination with a Porcine Reproductive and Respiratory Syndrome (PRRS) Modified Live Virus Vaccine Followed by Challenge with PRRS Virus and Porcine Circovirus Type 2 (PCV2) Protects against PRRS but Enhances PCV2 Replication and Pathogenesis CompaGenomic analysis of the differential response to experimental infection with porcine circovirus 2b.Efficacy of parenteral vaccination against porcine circovirus type 2 (PCV2) in seropositive piglets.Porcine circovirus type 2 (PCV2)-infection and re-inoculation with homologous or heterologous strains: virological, serological, pathological and clinical effects in growing pigs.High-level expression and immunogenicity of a porcine circovirus type 2 capsid protein through codon optimization in Pichia pastoris.An experimental live chimeric porcine circovirus 1-2a vaccine decreases porcine circovirus 2b viremia when administered intramuscularly or orally in a porcine circovirus 2b and porcine reproductive and respiratory syndrome virus dual-challenge modelCoinfection with Haemophilus parasuis serovar 4 increases the virulence of porcine circovirus type 2 in piglets.Influence of spray dried porcine plasma in starter diets associated with a conventional vaccination program on wean to finish performance.Serum haptoglobin dynamics in pigs vaccinated or not vaccinated against porcine circovirus type 2.Benefits of PCV-2 vaccination in pigs.Comparison of serum pools and oral fluid samples for detection of porcine circovirus type 2 by quantitative real-time PCR in finisher pigs.Evaluation of the Efficacy and Cross-Protective Immunity of Live-Attenuated Chimeric PCV1-2b Vaccine Against PCV2b and PCV2d Subtype Challenge in Pigs.Crystal Structure of the Dimerized N Terminus of Porcine Circovirus Type 2 Replicase Protein Reveals a Novel Antiviral InterfaceLongitudinal comparison of the humoral immune response and viral load of Porcine Circovirus Type 2 in pigs with different vaccination schemes under field conditions
P2860
Q26825289-D8438DC6-E3F7-4D7B-BEEA-65FC61F30845Q27304664-A9107D9A-2D07-4203-B30A-A48A0DB73946Q27326717-2746B315-E047-400E-8DDB-BCEEE2E91343Q30596525-BCAC70AC-1E98-4887-A642-294D4A7B1E45Q30832016-7A4286CD-8DBE-44B3-84F6-91B8F2E179B8Q33525023-FAEC5333-5E76-412D-89FD-BF02ACA75A83Q34431921-17AEFB47-DCDE-4556-825B-78C8CA6083B7Q35138806-D1A1EE26-3D3E-436F-9FC0-C43F1F37979EQ35142582-F6B69C4D-A391-4979-B308-0BBDD66477E0Q35199079-9961FD7E-39B7-4692-8B3E-69B02C168EF8Q35271142-853CBA25-38BD-4AE9-849C-1C989C952264Q35530199-6454DB00-AF91-4C86-8EE0-BEDFFFF64C4CQ35653521-840CBDA8-B91A-4C3A-B3BC-C1152DBC166AQ36015138-7225D1F7-FD4D-4FEA-B41A-0BA100B9C56EQ36061842-85B29B5F-60F9-4560-A931-26C636DCD827Q36414373-B22E8A78-F1E3-4B59-92FB-E0629CD93645Q36839257-18CFFA79-E4C1-4737-B3E5-B74EF104C311Q37213867-CC98EF87-A7C8-4950-A15F-737CE18BD8FDQ37425276-6DED6319-F414-435F-8A53-19F4BA91CAC2Q37581980-9DB16A52-BC69-4A3C-8575-1C02C64F752DQ37643346-F7BBC37C-8A64-45D3-8C82-2DFF9E768FCBQ37909427-37A02507-DB42-4ED2-9CAB-1F8F94A522D8Q38268599-AA643A16-A25F-4BAA-B1EE-AE6C4D6D7765Q38668708-AE6D69D9-2779-4C9F-B733-4E9BFA5946E9Q39914222-49622325-69B5-48A0-A4F6-1CFC3C31DBF0Q40352838-FE0829E7-0851-4973-8D0F-DF9B9A28D609Q40962177-1CED0F73-F3A2-4D97-B7C9-FDB2CB4B517CQ42242311-3B9CE924-1B0B-4608-9376-CD222704208DQ42562770-2145DD09-3316-4B56-9B64-2CEBDBF608FDQ42910025-79C3C6F9-59F0-4C00-80D1-D3721BA79C50Q43741583-1FEC1119-5BA8-46B4-A0A4-91C9F188731DQ45362988-B050441F-1B9B-4E13-85B7-A2DBABB1FB0CQ47108492-ABC44E9D-D91B-4117-8126-AD5DCBE0BE15Q51061483-81D6661D-F53B-43D6-930F-10D4B92E4E52Q51061490-B18B5255-65FB-4596-B796-A66839838375Q51064544-5958E975-E2E1-4FE1-B0A6-9F6349B9D066Q52696019-2026604F-52AE-4CEB-A3FB-E4F78645E73CQ55218539-89672538-60FA-4A90-AFBB-C8E1EC836579Q57753250-B04A3158-08E3-4833-890D-EA9091A887F3Q58693666-CE5D7486-5497-4161-8F55-5C36E6E196DE
P2860
Reduction of PMWS-associated clinical signs and co-infections by vaccination against PCV2.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Reduction of PMWS-associated c ...... s by vaccination against PCV2.
@en
Reduction of PMWS-associated c ...... s by vaccination against PCV2.
@nl
type
label
Reduction of PMWS-associated c ...... s by vaccination against PCV2.
@en
Reduction of PMWS-associated c ...... s by vaccination against PCV2.
@nl
prefLabel
Reduction of PMWS-associated c ...... s by vaccination against PCV2.
@en
Reduction of PMWS-associated c ...... s by vaccination against PCV2.
@nl
P2093
P1433
P1476
Reduction of PMWS-associated c ...... s by vaccination against PCV2.
@en
P2093
Knut Elbers
Marion Kixmöller
Matthias Eddicks
Vicky Fachinger
P304
P356
10.1016/J.VACCINE.2008.04.032
P407
P577
2008-05-05T00:00:00Z